Abstract:We thank Drs Zhang and Fan for highlighting the importance of our findings and appreciate the opportunity to respond to their concerns.1,2 We totally agree that “geneticrelated nonalcoholic fatty liver disease (NAFLD)” and “metabolicrelated NAFLD” exert different effects on cardiovascular diseases. Compared with the remarkably increased cardiovascular risk in metabolicrelated NAFLD,3 NAFLD caused by PNPLA3 and TM6SF2 gene variants seemed to have no causal relationship with cardiovascular diseases according to previous studies.4 This disparity could be explained by the inverse correlations of PNPLA3 and TM6SF2 gene variants with cardiovascular mortality found in our current study and previously.2,5 PNPLA3 rs738409 gene variant was an important cause of lean NAFLD clinically. Our previous study has revealed that the PNPLA3 gene variants influenced the liver steatosis and serum lipoprotein profiles not only in the overweight/obese people but also the lean people with metabolic dysfunction.6 Therefore, the PNPLA3 gene variant increased the liverspecific mortality and reduced cardiovascular mortality not only in the subgroups of overweight/obese people but also people with diabetes, hypertension, hyperlipidaemia and metabolic syndrome, regardless of body weight.2 Moreover, our study also indicated that serum VLDL1 triglyceride, a newly recognised liverderived biomarker for metabolic disorders, was regulated by PNPLA3 gene variant and might accurately predict the hepatic and extrahepatic effect of the PNPLA3 gene variant. Lean NAFLD is heterogeneous, which could be caused by a series of risk factors including visceral adiposity, sarcopenia and NAFLDrelated gene variants.7 Although a higher proportion of PNPLA3 gene variant might be found in the lean NAFLD patients, it could only explain the development of NAFLD in a portion of lean people (~30%) at best.8 We found that sarcopenia and central obesity could be diagnosed in a comparable portion (36.5% and 30.7%, respectively) of lean NAFLD patients aged over 45 years from Shanghai Changfeng Study, and the presence of sarcopenia or central obesity was significantly associated with the risk of carotid atherosclerosis1,9 in individuals with NAFLD. Therefore, instead of the genetic risk factors, other clinical risk factors of lean NAFLD, such as central obesity and sarcopenia, might have a dominant effect to determine their mortality from cardiovascular diseases. The menopause status and its related alteration in sex hormones might influence the clinical outcomes of generelated NAFLD as well. Oestrogen in the premenopausal women was found to be protective against the development and progression of NAFLD and cardiovascular diseases.10 It is possible that the effect of the PNPLA3 gene variant on liverspecific and cardiovascular mortality can be affected by individual sex hormone levels. However, in our study population aged averagely of 63.7 years, the number of premenopausal women was too small to identify the protective effect of oestrogen. In conclusion, NAFLDrelated gene variants influenced the hepatic and cardiovascular outcomes in Chinese adults with NAFLD, but these genetic risk factors were not the only determinant of their clinical outcomes. Thus, an accurate prediction of the clinical outcomes of NAFLD patients requires integrating individual genetic and metabolic risk factors.

Editorial: Opposite Effects of Genetic Polymorphisms Known to Induce NAFLD on Hepatic and Cardiovascular Outcomes in Chinese Population—authors' Reply

NAFLD‐related gene polymorphisms and all‐cause and cause‐specific mortality in an Asian population: the Shanghai Changfeng Study

Prevalence and Risk Factors for the Development of Nonalcoholic Fatty Liver Disease in a Nonobese Chinese Population: the Zhejiang Zhenhai Study.

Is Cigarette Smoking an Independent Risk Factor or a Cofactor for Nonalcoholic Fatty Liver Disease?

The PNPLA3 Rs738409 C>G Variant Influences the Association Between Low Skeletal Muscle Mass and NAFLD: the Shanghai Changfeng Study

Sex-specific Metabolic Risk Factors and Their Trajectories Towards the Non-Alcoholic Fatty Liver Disease Incidence.

The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes

Outcomes of Subjects Who Are Lean, Overweight or Obese with Nonalcoholic Fatty Liver Disease: A Cohort Study in China.

P21 Multisystem Health Consequences of Nonalcoholic Fatty Liver Disease: Phenome-Wide Mendelian Randomization and Disease-Trajectory Analyses

I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders

Hypertension and NAFLD Risk: Insights from the NHANES 2017-2018 and Mendelian Randomization Analyses.

Genetic Predisposition, Lifestyle Risk, and Obesity Associate with the Progression of Nonalcoholic Fatty Liver Disease

Abstract 13791: Non-Alcoholic Fatty Liver Disease Risk SNP Variants Affect Lipid Metabolism

PNPLA3 I148M Variant Affects Non-Alcoholic Fatty Liver Disease in Liver Transplant Recipients

Metabolic Risk Factors, Genetic Predisposition, and Risk of Severe Liver Disease in Chinese: a Prospective Study of 0.5 Million People

The association between rs1260326 with the risk of NAFLD and the mediation effect of triglyceride on NAFLD in the elderly Chinese Han population

Fasting glucose mediates the influence of genetic variants of SOD2 gene on lean non-alcoholic fatty liver disease

Risk factors and biomarkers of non-alcoholic fatty liver disease: an observational cross-sectional population survey

Impact of PNPLA3 in Lean Individuals and in Cryptogenic Steatotic Liver Disease

Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An updated meta-analysis

Factors Associated with Nonalcoholic Fatty Liver Disease in a Non-Overweight/Obese and Overweight/Obese Chinese Population at Risk for Metabolic Syndrome: A Cross-Sectional Multicenter Study